Indoco Remedies Limited — Investor Meet, 28-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Indoco Remedies Limited’s recent earnings call highlighted mixed financial performance for Q2 FY'25. While domestic business saw a 2.9% revenue increase to INR 2,346 million, international revenues fell significantly, with the U.S. business down from INR 814 million to INR 247 million. The company is focusing on internal efficiencies to improve future output. Key developments include the final ANDA approval from USFDA for Lofexidine tablets and continued remediation efforts at manufacturing sites.